Likewise, Nilotinib was shown to have a synergistic effect with doxorubicin in in vitro models of STS, by reverting doxorubicin-induced P-gp-mediated multidrug resistance and by inhibiting MRP-1 activity [82]. The gene discussed is PGP; the disease is telomere syndrome.